Researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have made a groundbreaking discovery in the field of inherited neuropathies, identifying mutations in the ARHGAP19 gene as a novel cause of Charcot-Marie-Tooth disease (CMT), one of the most common inherited neurological disorders. Published in the prestigious Journal of Clinical Investigation, this international collaboration sheds new light on the genetic underpinnings of motor-predominant neuropathy, offering hope for improved diagnosis and targeted therapies for affected families worldwide.

Charcot-Marie-Tooth disease, named after the three physicians who first described it in 1886, encompasses a group of progressive disorders that damage peripheral nerves, leading to muscle weakness, sensory loss, and foot deformities. In Canada, CMT affects approximately 1 in 2,500 people, translating to around 15,000 individuals living with the condition. Symptoms often begin in adolescence or early adulthood, starting with foot drop and high arches, progressing to hand involvement and mobility challenges.

🧬 The ARHGAP19 Gene: A Key Regulator Disrupted

The ARHGAP19 gene encodes a Rho GTPase activating protein (GAP), specifically targeting RhoA, a small GTPase critical for cytoskeletal dynamics, cell migration, and myelination in Schwann cells—the cells that insulate peripheral nerves. Biallelic loss-of-function variants (homozygous or compound heterozygous mutations) in ARHGAP19 lead to hyperactivation of RhoA, disrupting normal nerve function and causing a motor-predominant neuropathy with conduction slowing.

This recessive form of CMT was previously undiagnosed in many patients, highlighting the genetic heterogeneity of the disease. The study identified 16 distinct variants across 25 patients from 20 unrelated families spanning multiple ethnicities, confirming segregation with disease in families.

Unraveling the Mystery: Study Methods and Patient Cohort

Led by Senior Scientist Nathalie Lamarche-Vane, PhD, from RI-MUHC's Cancer Research Program, the team employed whole-exome sequencing on undiagnosed CMT patients from international cohorts. Patients presented with early-onset (childhood to early adulthood) progressive weakness, particularly in lower limbs, mild sensory loss, and slowed nerve conduction velocities atypical for axonal CMT.

• Patient ages at onset: 2-30 years.
• Symptoms: Foot drop, steppage gait, hand tremors, scoliosis in some.
• Electrophysiology: Demyelinating features with conduction velocities 20-35 m/s.
• Functional validation: Patient fibroblasts showed reduced ARHGAP19 protein; RhoA pull-down assays confirmed impaired GAP activity.

Collaborators included teams from the UK (St George's University London), Turkey, and others, pooling data from rare disease registries.

In zebrafish models, arhgap19 knockdown recapitulated neuropathy phenotypes, with disrupted actin dynamics in motor neurons. Mouse studies are underway to further elucidate dosage effects.

Clinical Implications: From Diagnosis to Precision Medicine

This discovery expands the genetic landscape of CMT, now with over 100 known genes. For Canadian patients, where genetic testing rates are rising through provincial programs, ARHGAP19 screening could resolve up to 5-10% of undiagnosed cases. Early diagnosis enables multidisciplinary management: orthotics, physiotherapy, and monitoring for complications like respiratory involvement.Read the full RI-MUHC announcement.

Treatment remains symptomatic, but RhoA inhibitors (e.g., fasudil, in trials for other neuropathies) emerge as candidates. Gene therapy approaches targeting loss-of-function could restore GAP activity.Access the JCI paper.

Spotlight on Lead Researcher: Nathalie Lamarche-Vane's Expertise

Prof. Lamarche-Vane, a Professor at McGill University's Department of Anatomy and Cell Biology, has dedicated her career to Rho GTPase signaling in cancer and neurodegeneration. "This study shows that ARHGAP19 plays an essential role in maintaining healthy motor neurons. When the gene does not function properly, it leads to nerve damage," she stated.

Her lab's integration of genetic, cellular, and animal models exemplifies translational research at RI-MUHC, bridging basic science to clinical impact. For aspiring researchers, explore higher ed jobs in neurogenetics at Canadian universities.

CMT in Canada: Prevalence, Challenges, and Ongoing Research

Canada's CMT community benefits from networks like the Canadian Neuromuscular Disease Registry and Inherited Neuropathy Consortium. Recent studies report genetic diagnoses in 60-70% of cases, up from 30% a decade ago, thanks to next-gen sequencing.

• Pediatric CMT cohort (Ontario): 40% axonal, 30% demyelinating, 30% intermediate.
• Challenges: Delayed diagnosis (avg 5-10 years), access to genetic counseling in rural areas.
• Ongoing: Clinical trials for PXT30040, ACE-083 at Canadian sites.

McGill and RI-MUHC lead in neurogenomics, with spin-offs to patient registries.

Related Canadian efforts include genomic surveillance at BC Children's Hospital and functional studies at UofT. This ARHGAP19 finding aligns with national priorities in rare disease genomics via Genome Canada.

Stakeholder Perspectives: Patients, Clinicians, and Families

Families in the study reported relief: one index case, a 15-year-old with bilateral foot drop since age 5, now has a genetic explanation. Clinicians note asymmetry and conduction slowing distinguish this subtype. Patient advocacy groups like CMT Awareness Canada hail it as a step toward personalized care.

"Genetic discoveries like this empower families and guide therapy development," says a spokesperson from Hereditary Neuropathy Foundation of Canada.

Future Outlook: Therapeutic Horizons and Research Roadmap

Short-term: Incorporate ARHGAP19 into CMT gene panels. Long-term: Rho pathway modulators in preclinical models. RI-MUHC plans patient registries and iPSC-derived motor neuron studies. Funding from CIHR supports expansion.RI-MUHC Research.

Canada's strengths in genomics position it to lead global CMT trials. Check higher ed career advice for neurogenetics paths.

Photo by Sangharsh Lohakare on Unsplash

Conclusion: A Milestone in Canadian Neurogenomics

The ARHGAP19 discovery exemplifies RI-MUHC's impact, advancing from gene hunt to mechanism. For patients, it's closure and hope; for researchers, a RhoA target in neuropathy. Explore faculty positions at higher-ed-jobs/faculty, rate professors on Rate My Professor, or find university jobs via university-jobs. Stay informed on breakthroughs shaping tomorrow's medicine.